BDBM50243842 CHEMBL4066404::US10966980, Example 80

SMILES: CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12

InChI Key: InChIKey=WGAJDNFRQOWUQD-OKILXGFUSA-N

Data: 9 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 50243842   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	19	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Inhibition of recombinant human JAK1 using 5'FAM-KKSRGDYMTMQID as substrate in presence of 1 mM ATP by mobility shift assay				J Med Chem 61: 1130-1152 (2018) Article DOI: 10.1021/acs.jmedchem.7b01598 BindingDB Entry DOI: 10.7270/Q2D79DTW
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	>2.00E+5	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Inhibition of recombinant human TYK2 using 5'FAM-KKSRGDYMTMQID as substrate in presence of 1 mM ATP by mobility shift assay				J Med Chem 61: 1130-1152 (2018) Article DOI: 10.1021/acs.jmedchem.7b01598 BindingDB Entry DOI: 10.7270/Q2D79DTW
					More data for this Ligand-Target Pair
JAK1/TYK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	645	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor				J Med Chem 61: 1130-1152 (2018) Article DOI: 10.1021/acs.jmedchem.7b01598 BindingDB Entry DOI: 10.7270/Q2D79DTW
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	>2.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Inhibition of JAK2 in CD34+ human whole blood assessed as reduction in EOP induced STAT5 phosphorylation preincubated for 45 mins followed by EOP add...				J Med Chem 61: 1130-1152 (2018) Article DOI: 10.1021/acs.jmedchem.7b01598 BindingDB Entry DOI: 10.7270/Q2D79DTW
					More data for this Ligand-Target Pair
Non-receptor tyrosine-protein kinase TYK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	2.20E+3	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. US Patent					Assay Description Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovi...				US Patent US10966980 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK1 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	17	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. US Patent					Assay Description Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovi...				US Patent US10966980 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	886	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. US Patent					Assay Description Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovi...				US Patent US10966980 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK3 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	US Patent	n/a	n/a	1.00E+4	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. US Patent					Assay Description Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4, 10 mM magnesium chloride, 0.01% bovi...				US Patent US10966980 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase JAK2 (Homo sapiens (Human))	BDBM50243842 (CHEMBL4066404 | US10966980, Example 80) Show SMILES CCCCN(C)S(=O)(=O)C[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |r,wD:12.14,10.9,(20.04,-11.87,;18.7,-12.63,;17.37,-11.86,;16.03,-12.62,;14.69,-11.84,;14.7,-10.3,;13.35,-12.61,;14.12,-13.94,;12.58,-13.93,;12.02,-11.85,;10.69,-12.62,;9.2,-12.23,;8.81,-13.72,;10.3,-14.11,;7.48,-14.5,;6.15,-13.73,;7.49,-16.04,;6.16,-16.81,;6.15,-18.35,;7.49,-19.12,;8.83,-18.34,;10.3,-18.81,;11.2,-17.56,;10.29,-16.31,;8.82,-16.8,)| Show InChI InChI=1S/C17H27N5O2S/c1-4-5-8-21(2)25(23,24)11-13-9-14(10-13)22(3)17-15-6-7-18-16(15)19-12-20-17/h6-7,12-14H,4-5,8-11H2,1-3H3,(H,18,19,20)/t13-,14+	PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	888	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Inhibition of recombinant human JAK2 using FITC-KGGEEEEYFELVKK as substrate in presence of 1 mM ATP by mobility shift assay				J Med Chem 61: 1130-1152 (2018) Article DOI: 10.1021/acs.jmedchem.7b01598 BindingDB Entry DOI: 10.7270/Q2D79DTW
					More data for this Ligand-Target Pair